Table 2.
Patient Characteristics in the two Cohorts
| Institute | No (%) | ||
|---|---|---|---|
| Characteristics | JHH (n=502) | MSKCC (n=747) | P |
| Patient characteristics | |||
| Age, years, Median (IQR) | 58.4 (49.8–66.4) | 58.1 (49.2–67.2) | 0.816 |
| CRC nodal metastases | 0.164 | ||
| Negative | 163 (32.5) | 272 (36.4) | |
| Positive | 339 (67.5) | 475 (63.6) | |
| Disease-free interval | 0.067 | ||
| < 12 months | 369 (73.5) | 583 (78.0) | |
| ≥ 12 months | 133 (26.5) | 164 (22.0) | |
| Preoperative CEA, ng/mL | 0.971 | ||
| Median, (IQR) | 7.6 (3.5–21.3) | 7.0 (3.4–22.1) | |
| Extrahepatic disease at the time of operation | 0.367 | ||
| Negative | 452 (90.0) | 684 (91.6) | |
| Positive | 50 (10.0) | 63 (8.4) | |
| No. of CRLM, Median (IQR) | 2 (1–4) | 2 (1–4) | 0.853 |
| Size of largest CRLM, cm, Median, (IQR) | 2.6 (1.6–4.1) | 2.5 (1.6–4.2) | 0.945 |
| KRAS mutation status | 0.551 | ||
| Wild-type | 320 (63.7) | 463 (62.0) | |
| Mutated | 182 (36.3) | 284 (38.0) | |
CEA, carcinoembryonic antigen; CRC, colorectal cancer; CRLM, colorectal liver metastases; IQR, interquartile range